Stockwatch: Antibodies And Coronavirus – It’s Complicated

Monoclonal Antibodies Have A Poor Antiviral Track Record

The use of antibodies in disease prevention and treatment is now ingrained in modern medicine but as antiviral agents their record is at best patchy and the reliance on them to treat or prevent coronavirus infections is perhaps premature.

StockWatch_Andy-Smith_V2_1200.jpg
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from COVID-19

More from Scrip